MadeMed vs Garcia Weight Loss, Aesthetics & Hormone Therapy
Two GLP-1 desks, one scoreboard. We put MadeMed and Garcia Weight Loss, Aesthetics & Hormone Therapy head-to-head on the published Brief Score — the same six factors, scored the same way.
MadeMed
Garcia Weight Loss, Aesthetics & Hormone Therapy
The verdict
MadeMed takes this head-to-head.
MadeMed scores 86 to 61 on our six-factor Brief Score — Publishes a price for every dose of every route — which makes it easy to brief, and expensive if you stay low.
That doesn't make Garcia Weight Loss, Aesthetics & Hormone Therapy a bad call — it's best for readers who want florida residents who want an established in-person weight-loss clinic with provider-supervised glp-1 care. Weigh the six factors below against your own priorities before you decide.
Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes the Brief Score.
Factor by factor
Both desks scored on the six published Brief Score factors. The higher score in each row is marked. See the methodology.
Price, coverage & the tracker
| MadeMed | Garcia Weight Loss, Aesthetics & Hormone Therapy | |
|---|---|---|
| Brief Score | 86/100 (B) | 61/100 (C) |
| Semaglutide | $239/mo injectable · $219/mo sublingual (quarterly) | From $400/mo (starting dose, compounded) |
| Tirzepatide | $399/mo injectable · $299/mo sublingual (quarterly) | Not disclosed |
| Coverage | 40 states | 1 states |
| Brand-name access | Compounded only | Compounded only |
| Oral / sublingual | Yes | Injection only |
| On the tracker | Stableprice stable | Newnew to the tracker, no prior reading |
MadeMed: Publishes one price per route that holds at every dose — the cleanest dose-to-price mapping we track.
Garcia Weight Loss, Aesthetics & Hormone Therapy: New to the tracker on 1 August 2026. The published line reads From $400/mo (starting dose, compounded) at our first reading; there is no earlier reading of ours to compare it against yet.
● Not sold on either?
CoreAge Rx tops the whole board at 94/100.
The steadiest desk on the board: one flat, no-step-up price on both molecules, nationwide, and it hasn't moved.
Keep comparing
Pricing, states and access reflect each provider's public disclosures at last review; the Brief Score is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.